

Programme

Confirmed Plenary Speakers (to Date)

QBW251: a Potent Potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel for Treatment of Respiratory Diseases

Dr Atwood CHEUNG

(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States)

The Discovery of BMS-986177/JNJ-70033093; a FXIa Inhibitor for the Prevention and Treatment of Thrombosis

Dr Andrew DILGER

(BRISTOL-MYERS SQUIBB, Princeton, United States)

First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases

Dr Riccardo GIOVANNINI

(BOEHRINGER INGELHEIM, Biberach, Germany)

Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other

Dr Uwe GREETHER

(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations

Dr Wooseok HAN

(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Songpa-gu, Korea, South)

Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH

Dr Naoyoshi NOGUCHI

(SCOHIA PHARMA, INC., Fujisawa, Japan)

Discovery of AZD8154, a Dual PI3K?? Inhibitor, as an Inhaled Treatment for Asthma

Dr Matthew W. D. PERRY

(ASTRAZENECA, Gothenburg, Sweden)

Discovery of the AhR Antagonist BAY 2416964; a New Clinical Candidate for Cancer Immunotherapy

Dr Norbert SCHMEES

(BAYER PHARMACEUTICALS, Berlin, Germany)

GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH)

Dr Fredrik ZETTERBERG

(GALECTO BIOTECH, Gothenburg, Sweden)

Confirmed Speakers

EFMC-ISM Virtual Event 2020

Programme

Monday September 7, 2020

EFMC-ISM Virtual Event 2020 - Day 1

- 17:00 Opening Address by EFMC President**
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
- 17:10 Session Chair**
Prof. Karl-Heinz ALTMANN
(ETH ZÜRICH, Zürich, Switzerland)
- 17:15 Discovery of the AhR Antagonist BAY 2416964; a New Clinical Candidate for Cancer Immunotherapy**
Dr Norbert SCHMEES
(BAYER PHARMACEUTICALS, Berlin, Germany)
- 17:45 Discovery of AZD8154, a Dual PI3K?? Inhibitor, as an Inhaled Treatment for Asthma**
Dr Matthew W. D. PERRY
(ASTRAZENECA, Gothenburg, Sweden)
- 18:15 The Discovery of BMS-986177/JNJ-70033093; a FXIa Inhibitor for the Prevention and Treatment of Thrombosis**
Dr Andrew DILGER
(BRISTOL-MYERS SQUIBB, Princeton, United States)
- 18:45 QBW251: a Potent Potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel for Treatment of Respiratory Diseases**
Dr Atwood CHEUNG
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States)
- 19:15 Closing Remarks**
Prof. Karl-Heinz ALTMANN
(ETH ZÜRICH, Zürich, Switzerland)
- 19:20 End of Day 1**

EFMC-ISM Virtual Event 2020

Programme

Tuesday September 8, 2020

EFMC-ISM Virtual Event 2020 - Day 2

- 16:00 Opening Address by EFMC-ISM Chairman**
Prof. Karl-Heinz ALTMANN
(ETH ZÜRICH, Zürich, Switzerland)
- 16:10 Session Chair**
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
- 16:15 Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH**
Dr Naoyoshi NOGUCHI
(SCOHIA PHARMA, INC., Fujisawa, Japan)
- 16:45 The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations**
Dr Wooseok HAN
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Songpa-gu, Korea, South)
- 17:15 GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH)**
Dr Fredrik ZETTERBERG
(GALECTO BIOTECH, Gothenburg, Sweden)
- 17:45 First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases**
Dr Riccardo GIOVANNINI
(BOEHRINGER INGELHEIM, Biberach, Germany)
- 18:15 Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other**
Dr Uwe GREETHER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)
- 18:45 Closing Remarks, EFMC-ISM 2021 and EFMC Events**
Prof. Karl-Heinz ALTMANN (ETH ZÜRICH, Zürich, Switzerland)
Dr Yves P. AUBERSON (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
- 19:00 End of the EFMC-ISM Virtual Event 2020**